Not enough is known about these drugs.
We need a more comprehensive and perhaps more effective strategy in controlling acute respiratory infections, relying on several preventive interventions that take into account the multi-agent nature of infectious respiratory disease and its context (such as personal hygiene, provision of electricity and adequate food, water and sanitation).
The bottom line is the effectiveness is modest, at best. It's very disappointing.
The runaway 100 percent effectiveness that's touted by proponents was nowhere to be seen.
All this homework should be done before the vaccine is recommended for use in any population, not after.
There are no comparative studies on avian flu. We're not saying drugs shouldn't be given. We just don't know. The jury is out.
Our findings show that, according to reliable evidence, the effectiveness of trivalent inactivated influenza vaccines in elderly individuals is modest, irrespective of setting, outcome, population, and study design.
People should ask whether it's worth investing these trillions of dollars and euros in these vaccines.
This is not a surprise and people should not be prescribing them without an accurate diagnosis or a high clinical suspicion because they know that influenza is circulating in the community. The downside of that is the cost, creating resistance, adverse events and no effectiveness. It just doesn't work.
What you see is that marketing rules the response to influenza, and scientific evidence comes fourth or fifth. Vaccines may have a role, but they appear to have a modest effect. The best strategy to prevent the illness is to wash your hands.
If you're going to use these neuraminidase inhibitors, you shouldn't be using them as a single solution. You should also use public health measures.
Copyright © 2024 Electric Goat Media. All Rights Reserved.